This is an aggregated industry headline. Read the full story at BioPharma Dive →
Gene editing developer Scribe plots an IPO
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
By BioPharma Dive
· Jul 6, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Skin quality affects quality of life for 85% of people, leaving more than one-third of individuals feeling sel…
The WeekFierceBiotech ↗
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipi…
The WeekBriefing
Anthropic’s CEO urged realism on AI drug discovery as Medicare floated sharp 340B payment cuts, setting diverg…